Efficacy of Ivermectin in the Treatment of Plane Warts

NCT07710638 | Active Not Recruiting Phase 2

• 1 other identifier: AZHAR-DERM-2025-001
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the efficacy of ivermectin in the treatment of plane warts( flat warts). patients diagnosed with plane warts will be included to assess the clearance ratre of the lesions.

Conditions

Plane Warts

Keywords

ivermectin

Outcome Measures

Primary Outcomes (1)

• percentage of patients achieving complete clearance of plane warts

  3 months

Study Arms (4)

Group1 : topical ivermectin

EXPERIMENTAL

Patients will receive topical ivermectin cream applied twice daily to plane warts for 3 months

Drug: Ivermectin

Group 2 : oral ivermectin

EXPERIMENTAL

Patients will receive oral ivermectin once weekly for 3 months

Drug: Ivermectin

control group 1

PLACEBO COMPARATOR

Other: Placebo

control group 2

PLACEBO COMPARATOR

Other: Placebo

Interventions

Ivermectin DRUG

An antiparasitic medication evaluated for its immunomodulatory and antiviral efficacy in clearing plane warts. it will be administered to patients according to their assigned group protocol.

Group 2 : oral ivermectin; Group1 : topical ivermectin

Placebo OTHER

Patients in the control group will receive placebo,they will undergo standard clinical observation and follow up to monitor the natural course of the plane warts.

control group 1; control group 2

Eligibility Criteria

• Age: 5 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• No prior treatment for warts in the last 4 weeks.
• Patients of both sex (male - female)
• Age more than 5 years or weight more than 15 kg.

You may not qualify if:

• Patients with other types of warts (e.g., common, plantar, genital).
• History of hypersensitivity or allergy to ivermectin or its components.
• Patients who have received systemic immunosuppressive therapy within the last 3 months.
• Presence of chronic skin conditions that may interfere with evaluation (e.g., eczema, psoriasis).
• Patients with immunodeficiency disorders (e.g., HIV, organ transplant recipients).
• Pregnant or lactating females.
• Patients currently on systemic antiviral or immunomodulatory treatment.

Sponsors & Collaborators

• Al-Azhar University: lead

Study Sites (1)

Department of Dermatology , Al-Azhar university hospital

Asyut, Egypt

Location

MeSH Terms

Interventions

Ivermectin

Intervention Hierarchy (Ancestors)

Macrolides; Polyketides; Lactones; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of dermatology

Study Record Dates

• First Submitted: July 14, 2026
• First Posted: July 17, 2026
• Study Start: June 1, 2026
• Primary Completion: June 1, 2026
• Study Completion (Estimated): June 1, 2027
• Last Updated: July 17, 2026

Record last verified: 2026-07

Locations

EG (1)